Novome Biotechnologies locks in $33 mln Series A

South San Francisco-based Novome Biotechnologies Inc, a provider of living medicines for chronic diseases, has secured $33 million in Series A financing.

South San Francisco-based Novome Biotechnologies Inc, a provider of living medicines for chronic diseases, has secured $33 million in Series A financing. DCVC Bio led the round with participation from 5AM Ventures, Alta Partners, Alexandria Venture Investments and Mayo Clinic.

Source: Press Release